ARID1A and ovarian cancer: unveiling the direct repression of AURKA by ARID1A (102), studies have been conducted with pan-aurora kinase inhibitors in colon and ovarian cancer cells with ARID1A deficiency, causing chromosomal abnormalities leading to synthetic lethality (103).